Semaglutide injection at New Results Medical Weight Loss

Semaglutide Compounding Restrictions

FDA’s Latest on Semaglutide Compounding

In February 2025, the FDA issued a Declaratory Order confirming that the national shortage of semaglutide injections (e.g., Ozempic®, Wegovy®) has been resolved and clarifying compounding policies for GLP‑1 products like semaglutide.

Under this guidance:

  • 503A compounding pharmacies may no longer compound “essentially a copy” of semaglutide once the commercial supply is sufficient.

  • Outsourcing facilities (503B) have 60 days to cease compounding semaglutide-based drugs that duplicate approved products.

 

Why Compounding Was Permitted, and Why It’s Changing

Photo of Semaglutide for weight loss

During the two‑year GLP‑1 shortage, compounding pharmacies played a vital role under the FDA’s shortage exception (FD&C Act § 506C), allowing them to prepare semaglutide when branded supply couldn’t meet demand. Now that Novo Nordisk and other manufacturers confirm stable output, the FDA is enforcing the “essentially a copy” prohibition to protect patient safety and uphold the drug‑approval process.

Providers must document a “significant difference” for any compounded version- simply seeking a cheaper alternative or combining additives (e.g., B12, glycine) no longer suffices. 

 Impact on Patient Access & Affordability

With compounding pipelines closing, many patients- especially those relying on lower‑cost compounded semaglutide- face reduced options. Recent reports highlight:

  • A federal judge upheld the FDA’s removal of semaglutide from the shortage list, forcing compounding facilities to halt production by May 22, 2025.

  • Patients are scrambling for alternatives: some are stockpiling vials, others are turning to oral Rybelsus® (semaglutide tablets) or seeking telehealth suppliers abroad.

 

Safe, FDA‑Approved Alternatives

Client getting injected with a GLP-1.

If you’ve been using compounded semaglutide, here’s what to consider next:

  1. Branded Injectables: Wegovy® and Ozempic® remain FDA‑approved for weight management and diabetes; many insurance plans cover them with prior authorization.

  2. Oral Semaglutide: Rybelsus® offers a daily tablet option, though it requires fasting before dosing and specific administration guidelines.

  3. Other GLP‑1s: Tirzepatide (Mounjaro®/Zepbound®) may be appropriate if covered by your plan or as part of a clinical discussion.

External link suggestion: Read the full FDA Declaratory Order on compounded GLP‑1s at the FDA’s website.

 

Next Steps at New Results Medical Weight Loss

At New Results Medical Weight Loss (Mesa & Scottsdale), our board‑certified obesity specialists can help you transition smoothly:

  • Insurance Navigation for branded semaglutide coverage

  • Telehealth & In‑Clinic Visits to maintain continuity of care

  • Dose Optimization and patient education on administration

  • Alternative Therapy Planning (oral semaglutide, tirzepatide, diet/exercise integration)

📞 Call us today or book online to discuss which FDA‑approved GLP‑1 option best fits your health goals, and ensure uninterrupted access to the therapies you need.